OCT 11, 2016 12:32 PM PDT

How Epstein-Barr Virus Evades the Immune System

WRITTEN BY: Kara Marker
The Epstein-Barr Virus (EBV), infamously known for causing bouts of mononucleosis, was originally discovered in 1964 in tissue from a Burkitt lymphoma tumor. Whether it is a college student dealing with an incapacitating mono infection or another individual dealing with a serious EBV-related tumor growth, the virus has a way of exacerbating these conditions by evading the immune system, and scientists are swiftly figuring out how to prevent it from doing so. 
The Epstein-Barr virus prevents infected cells from being attacked by the immune system.
From Helmholtz Zentrum München, the German Research Center for Environmental Health, scientists studied how EBV particles take over B lymphocytes and force them to proliferate without warning other immune cells of the EBV infection. They found that the viral particles produce microRNAs that prevent the normal alarm signal that is sent out by an infected B lymphocyte, so other immune cells could pass by with no reason to believe that the infected cell was under any duress.

"The mechanism we discovered renders killer T cells and helper T cells inactive, even when they directly face the infected cell," said study leader Wolfgang Hammerschmidt.

Normally, infected cells signal to the immune system via molecular pieces of the virus infected them on the cell surface for all to see. However, EBV-associated microRNAs block the production of the proteins required for putting this alert response into action.

"If it were possible to disrupt this blockade, this could be an interesting approach to treat cancer,” Hammerschmidt explained. “The immune system could then better fight tumors that are triggered by EBV."

EBV, also known as human herpesvirus 4, is actually commonly spread among humans through bodily fluids, most often saliva, which is why some refer to mononucleosis as “the kissing disease.” The Centers for Disease Control and Prevention states that most people get infected with EBV at some point in their lives, but usually a healthy immune system can keep an infection at bay.

In addition to targeting cases of mononucleosis, which has no specific treatment options, Hammerschmidt’s findings could be also be helpful in treating EBV-related cases of cancer. EBV was the first virus to be shown to cause cancer in humans, and it is associated with a wide variation of human cancers. 

Hammerschmidt’s study was recently published in the journal Proceedings of the National Academy of Sciences.
 


Sources: CDC, Experimental and Molecular Medicine, Helmholtz Zentrum München
Image: Prof. Georg Bornkamm / Helmholtz Zentrum München
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
Potential Cure for Coronavirus Found in Thailand
Doctors in Thailand have successfully treated people affected by the coronavirus via a new drug cocktail made out of ant ...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
China Begins Trials for Antiviral Drug to Tackle Coronavirus
So far, coronavirus has infected over 31,493 people globally, and has killed 638. Although 1,563 people have reportedly ...
FEB 21, 2020
Drug Discovery & Development
FEB 21, 2020
Why is it so Difficult to Develop a Vaccine for Coronavirus?
As of February 21st, 2,250 have died worldwide from Coronavirus, while 18,862 have recovered and 55,703 are currently in ...
APR 13, 2020
Drug Discovery & Development
APR 13, 2020
Are COVID-19 Antibody Tests a Back-to-Work Pass?
Although treatments and vaccines against COVID-19 may still be months away, antibody tests are becoming more widespread. ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Gilead's Remdesivir Trial Sees Rapid Recoveries from COVID-19
Early results from a Chicago hospital treating patients with Gilead Sciences’ antiviral drug remdesivir for severe ...
APR 11, 2020
Drug Discovery & Development
APR 11, 2020
Promising Experimental Anti-Malarial Drug
At St. Jude Children’s Research Hospital, researchers discovered a fast-acting anti-malarial compound with promisi ...
Loading Comments...